Clinical Success and del-brax's Mechanism of Action

Novartis' delpacibart braxlosiran (del-brax), acquired through the acquisition of Avidity Biosciences, has demonstrated positive biomarker data in the Phase 1/2 FORTITUDE trial. This drug is an antibody-oligonucleotide conjugate (AOC) that combines a transthyretin receptor 1 (TfR1)-targeting antibody with an siRNA payload, inhibiting the expression of the DUX4 gene, the root cause of facioscapulohumeral muscular dystrophy (FSHD). In this trial, del-brax significantly reduced KHDC1L, a downstream biomarker of DUX4, and creatine kinase, a marker of muscle damage. This demonstrates that the drug can be accurately delivered to target muscle cells, directly blocking the molecular pathway of the disease.

Novartis' Strategic Portfolio Expansion and Accelerated Development

In February of this year, Novartis completed the acquisition of Avidity for approximately $12 billion, incorporating del-brax as a key asset in its neuromuscular pipeline. The successful Phase 1/2 data not only validated the large-scale merger and acquisition in a short period but also significantly increased the possibility of accelerated approval. Novartis is already enrolling patients in the Phase 3 FORTITUDE-3 trial, with a dosing regimen of 2 mg/kg every six weeks, and is accelerating development. Based on the accumulated data, the company plans to promptly initiate discussions with global regulatory agencies, including the U.S. Food and Drug Administration (FDA), regarding the approval of the new drug.

A New Paradigm in the Treatment of Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) is a rare disease that progressively impairs patients' physical function, but there are currently no approved disease-modifying therapies. As an unmet medical need, the current market size is estimated at $210 million to $600 million, and the launch of a new drug is expected to create a blockbuster market of over $600 million annually by the mid-2030s. If del-brax is ultimately approved, it will fundamentally change the existing standard of care, which relies on symptom management and simple physical therapy, and become a first-in-class therapy.

Diversification of Neuromuscular Pipeline and Market Prospects

Del-brax has already received orphan drug and fast-track designations from the U.S. FDA and the European Medicines Agency (EMA), securing numerous regulatory benefits. With this success, Novartis has simultaneously increased the value of its neuromuscular pipeline, including del-desiran, targeting myotonic dystrophy type 1 (DM1), and del-zota, targeting Duchenne muscular dystrophy (DMD), in addition to del-brax. In particular, the release of del-desiran data is scheduled for the second half of the year, further solidifying its position to lead the next-generation RNA therapeutics market and strengthen its technological leadership in the industry.